Predicting human hepatic clearance from in vitro drug metabolism and transport data: a scientific and pharmaceutical perspective for assessing drug-drug interactions.
about
Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptidesReduced physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction risk.Primary hepatocyte cultures as prominent in vitro tools to study hepatic drug transporters.Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism.Prediction of drug disposition on the basis of its chemical structure.Experimental models for predicting drug absorption and metabolism.Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved.Dealing with the complex drug-drug interactions: towards mechanistic models.BDDCS, the Rule of 5 and drugability.Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS).Drug Disposition Classification Systems in Discovery and Development: A Comparative Review of the BDDCS, ECCS and ECCCS Concepts.Predictions of bisphenol A hepatic clearance in the isolated perfused rat liver (IPRL): impact of albumin binding and of co-administration with naproxen.High prevalence of potential drug-drug interactions in patients with castration-resistant prostate cancer treated with abiraterone acetate.Application of the extended clearance concept classification system (ECCCS) to predict the victim drug-drug interaction potential of statins.Mechanism-based pharmacokinetic modeling to evaluate transporter-enzyme interplay in drug interactions and pharmacogenetics of glyburide.Transporter-Enzyme Interplay: Deconvoluting Effects of Hepatic Transporters and Enzymes on Drug Disposition Using Static and Dynamic Mechanistic Models.
P2860
Q24564462-A8327B42-96E6-4D45-B1EE-49274060AF98Q30776360-DF3D1BB8-2A4C-4492-9CF1-87D5FBE9182AQ38077993-58DE2AB1-1601-406F-AB1B-D8B6EE25A1C1Q38084901-12B28261-E769-4CE8-8CCC-A67C68FC118EQ38086778-D59222DE-0918-48F8-A450-405857FE2D11Q38107970-0E6D34E3-02D4-46C7-B778-EB99B6B3378EQ38233298-1B87DDE6-CB22-41EF-B3BE-8E46915686B2Q38302225-3E07E65A-7409-4AB7-BEEC-C0ADB69F806FQ38835159-A1F9F7AA-5366-4F65-BF15-3225E0182B58Q38855314-103EAD54-90FB-4E40-8819-311875F5220DQ38903572-2F04E200-1D91-4146-947C-72FA589792CBQ38918303-83347E9D-3ABB-41B1-AA63-463910FD27EEQ38937142-C588577D-4C9A-4B66-8963-3FD092731F55Q40916355-EDC5A92A-C9D9-44F2-8551-57ED3A44B5C8Q41150870-CDD8EEB7-67B1-4C96-A37D-036FB58DC606Q45243894-9D00CDD6-38EC-4EB7-B08B-4810E6E28BBA
P2860
Predicting human hepatic clearance from in vitro drug metabolism and transport data: a scientific and pharmaceutical perspective for assessing drug-drug interactions.
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Predicting human hepatic clear ...... essing drug-drug interactions.
@ast
Predicting human hepatic clear ...... essing drug-drug interactions.
@en
Predicting human hepatic clear ...... essing drug-drug interactions.
@nl
type
label
Predicting human hepatic clear ...... essing drug-drug interactions.
@ast
Predicting human hepatic clear ...... essing drug-drug interactions.
@en
Predicting human hepatic clear ...... essing drug-drug interactions.
@nl
prefLabel
Predicting human hepatic clear ...... essing drug-drug interactions.
@ast
Predicting human hepatic clear ...... essing drug-drug interactions.
@en
Predicting human hepatic clear ...... essing drug-drug interactions.
@nl
P2860
P356
P1476
Predicting human hepatic clear ...... essing drug-drug interactions.
@en
P2093
Gian Camenisch
Ken-ichi Umehara
P2860
P304
P356
10.1002/BDD.1784
P577
2012-04-19T00:00:00Z